In recent works, we are testing intratumor delivery of GM-CSF using systemic PLGA/PEG-PLGA nanoparticles [161] as a method to remove excessive tumor VEGF that promotes vessel leakiness and aberrant sprouting, which in turn perpetuate tumor hypoxia leading to increased treatment resistance. This evidence concerns the gene CSF2 and neoplasm.